BioCentury
ARTICLE | Company News

Daiichi to market Esperion's LDL-C lowering products in Europe

January 4, 2019 8:03 PM UTC

Esperion Therapeutics Inc. (NASDAQ:ESPR) will get $150 million cash up front in exchange for granting the European subsidiary of Daiichi Sankyo Co. Ltd. (Tokyo:4568) exclusive rights to commercialize bempedoic acid (ETC-1002) and bempedoic acid/ezetimibe in the European Economic Area and Switzerland.

Esperion plans to submit MAAs to EMA next half for bempedoic acid as monotherapy and as a fixed-dose combination pill with ezetimibe for LDL-C-lowering cardiovascular indications...